Acadia Pharmaceuticals develops and sells medicines for neurological and rare diseases, including NUPLAZID and DAYBUE. It last closed at $17.11 on Nov 20, down 2.73% on the day. The next earnings report for ACAD is expected around Tue, Jan 12, 2027, after the close. For the quarter ended Sep 2026, ACAD reported EPS of $0.31 on revenue of $342.3M, with revenue up 22.8% from a year ago. Over its last 8 reports the stock moved an average of 4.4% the session after earnings. Over the last 12 months ACAD insiders bought $0 of stock on the open market and sold $2.5M, according to SEC Form 4 filings.
AI Auto Pilots
Is ACAD in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ACAD.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on ACADStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
ACAD · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 13% below its 20 day and 22% below its 50 day average. It is 35% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 34), near oversold. The nearest support is the Pivot S1 at $16.84, and the nearest resistance the Pivot at $17.32.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 5.5%/day
Key levels
$30.9652 week high+80.9%
$24.14100 day average+41.1%
$23.16200 day average+35.4%
$20.8050 day average+21.6%
$19.44Swing high (Nov 16)+13.6%
$19.3120 day average+12.9%
$17.58Pivot R1+2.7%
$17.32Pivot+1.2%
$17.11Last close
$16.84Pivot S1−1.6%
$15.8652 week low−7.3%
$15.86Swing low (Nov 9)−7.3%
Indicators
RSI (14)
34.22
Weak, oversold below 30
Neutral
MACD
-0.93
Below its signal line
Bearish
Stochastic
24.4
Middle of its range
Neutral
ADX (14)
32.3
Trending down
Williams %R
-81.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-106.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−19.4%
Change over 10 sessions
Bearish
ATR (14)
$0.95
Typical daily range, 5.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Turning down, nearing oversold
Short trendBearish
Long trendNeutral
MomentumWeak
StretchNear oversold
VolatilityHigh, 13.4%/day
Key levels
$30.9652 week high+80.9%
$24.14100 day average+41.1%
$23.16200 day average+35.4%
$20.8050 day average+21.6%
$19.44Swing high (Nov 16)+13.6%
$19.3120 day average+12.9%
$17.58Pivot R1+2.7%
$17.32Pivot+1.2%
$17.11Last close
$16.84Pivot S1−1.6%
$15.8652 week low−7.3%
$15.86Swing low (Nov 9)−7.3%
Indicators
RSI (14)
32.45
Weak, oversold below 30
Neutral
MACD
-1.48
Below its signal line
Bearish
Stochastic
16.7
Near the bottom of its range
Oversold
ADX (14)
27.2
Trending down
Williams %R
-91.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-113.0
Oversold below −100, overbought above 100
Oversold
Rate of change
−38.5%
Change over 10 sessions
Bearish
ATR (14)
$2.28
Typical daily range, 13.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ACAD
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ACAD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow ACAD usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for ACADHow many large options trades hit ACAD, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in ACAD in the last 90 days.
From SEC Form 4 filings by ACAD's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACAD is in one of them and how their past ACAD trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Acadia Pharmaceuticals
Acadia Pharmaceuticals is a drug company based in San Diego, California, that develops and sells medicines for neurological and rare diseases. Its main commercial products are NUPLAZID, used for hallucinations and delusions linked to Parkinson's disease psychosis, and DAYBUE, used to treat Rett syndrome. The company also develops earlier-stage product candidates, including treatments for Alzheimer's disease psychosis. Its medicines are prescribed to patients, mainly in the United States.